Search

Displaying results 731 - 740 of 4437 in total
  1. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.

    Products: Adempas 1mg film-coated tablet, ADEMPAS FILM-COATED TABLET 1.0mg
  2. Drug

    Sulpiride

    go.drugbank.com/drugs/DB00391
    ApprovedWithdrawn

    [A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]

    Products: SULPIRID HEXAL 50MG, SULPIRID STADA 50MG
  3. Drug

    Buserelin

    go.drugbank.com/drugs/DB06719
    ApprovedInvestigational

    Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.

    Products: Suprefact Liq 1mg/ml, Suprefact Inj 1mg/ml
  4. Drug

    Carmustine

    go.drugbank.com/drugs/DB00262
    ApprovedInvestigational

    A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be...

    Products: BICNU®-100MG, BICNU ® 100MG
  5. Drug

    Lycopene

    go.drugbank.com/drugs/DB11231
    Approved

    Lycopene is a naturally occurring red carotenoid pigment that is responsible for red to pink colors seen in tomatoes, pink grapefruit, and other foods . Having a chemical formula of C40H56, lycopene is a tetraterpene assembled from eight...

    Products: GNC Lycopene 15mg
  6. Drug

    Amodiaquine

    go.drugbank.com/drugs/DB00613
    ApprovedInvestigational

    A 4-aminoquinoquinoline compound with anti-inflammatory properties.

    Products: Sunoquine Tablet 100mg
  7. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase

    Products: NEXVIAZYME 100mg Powder for Concentrate for Solution for Infusion
  8. Drug

    Chlorprothixene

    go.drugbank.com/drugs/DB01239
    ApprovedInvestigationalWithdrawn

    Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

    Products: CHLORPROTHIXEN-NEURAX 50MG, CHLORPROTHIXEN-NEURAX 15MG
  9. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]

    Products: ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL
  10. Drug

    Cisatracurium

    go.drugbank.com/drugs/DB00565
    ApprovedInvestigational

    This action is antagonized by acetylcholinesterase inhibitors such as neostigmine.

    Products: Nimbex 10mg/ml, KABICURIUM® 10MG/5ML